Milatuzumab – a promising new immunotherapeutic agent

Milatuzumab is a new immunotherapeutic agent targeting CD74, a membrane protein preferentially expressed in hematopoietic cancers and some solid tumors. Broad expression and fast internalization makes CD74 an ideal target for cancer therapy. We reviewed published articles about CD74 and milatuzumab. We present a comprehensive review of CD74 functions and provide explanation of milatuzumab antitumor effects. This review describes CD74 protein biology with the emphasis on the role of CD74 in tumor survival and its new role in regulation of the Fas death receptor. The development of CD74 targeting therapies to induce tumor regression and cancer cell apoptosis is described and results of clinical trials are discussed. Milatuzumab shows selective binding and rapid internalization into CD74-positive cancer cells. Milatuzumab with and without conjugated toxins synergizes with other chemotherapeutic agents and elicits significant antitumor effects in mice. In a Phase I trial, milatuzumab showed no severe adverse effects in patients with relapsed/refractory multiple myeloma and it stabilized the disease in some patients for up to 12 weeks. Ongoing trials testing different treatment schedules of milatuzumab in chronic lymphocytic leukemia, non-Hodgkin's lymphoma and multiple myeloma indicate that milatuzumab shows no severe adverse effects in humans.

[1]  J. Bernhagen,et al.  A functional heteromeric MIF receptor formed by CD74 and CXCR4 , 2009, FEBS letters.

[2]  E. Dahl,et al.  Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer , 2009, BMC Cancer.

[3]  E. Beswick,et al.  CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract. , 2009, World journal of gastroenterology.

[4]  H. Eguchi,et al.  CD74 Is a Novel Prognostic Factor for Patients with Pancreatic Cancer Receiving Multimodal Therapy , 2009, Annals of Surgical Oncology.

[5]  J. M. Wilson,et al.  Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas. , 2009, European journal of cancer.

[6]  C. Metz,et al.  Macrophage CD74 contributes to MIF-induced pulmonary inflammation , 2009, Respiratory research.

[7]  D. Goldenberg,et al.  Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines , 2009, Clinical Cancer Research.

[8]  C. Wendtner,et al.  Overexpression of the Fas-inhibitory molecule TOSO–a novel antiapoptotic factor in chronic lymphocytic leukemia , 2009, Leukemia & lymphoma.

[9]  D. Siegel,et al.  First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma , 2008 .

[10]  D. Hawke,et al.  CD74 Is a Regulator of Fas-Mediated Apoptotic Signaling , 2008 .

[11]  S. Parmar,et al.  Treatment of AML in First Remission (CR1) with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Unrelated Donors (UD). , 2008 .

[12]  D. Wagner,et al.  Integrin-Independent Role of CalDAG-GEFI in Neutrophil Chemotaxis. , 2008 .

[13]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[14]  L. Leng,et al.  Macrophage Migration Inhibitory Factor Induces B Cell Survival by Activation of a CD74-CD44 Receptor Complex* , 2008, Journal of Biological Chemistry.

[15]  L. Leng,et al.  Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart , 2008, Nature.

[16]  L. Leng,et al.  CD74 induces TAp63 expression leading to B-cell survival. , 2007, Blood.

[17]  D. Goldenberg,et al.  CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms , 2007, Clinical Cancer Research.

[18]  A. Berrebi,et al.  IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival , 2007, Proceedings of the National Academy of Sciences.

[19]  E. Dahl,et al.  Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity , 2007, Oncogene.

[20]  J. Friedberg,et al.  Combination treatment approaches and novel therapies for lymphoma. , 2007, Clinical advances in hematology & oncology : H&O.

[21]  J. Bernhagen,et al.  MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment , 2007, Nature Medicine.

[22]  K. Iczkowski,et al.  Inhibition of Macrophage Migration Inhibitory Factor or Its Receptor (CD74) Attenuates Growth and Invasion of DU-145 Prostate Cancer Cells1 , 2006, The Journal of Immunology.

[23]  L. Leng,et al.  CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. , 2006, Immunity.

[24]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[25]  A. Berrebi,et al.  Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. , 2006, Blood.

[26]  S. Hirohashi,et al.  Establishment of Perineural Invasion Models and Analysis of Gene Expression Revealed an Invariant Chain (CD74) as a Possible Molecule Involved in Perineural Invasion in Pancreatic Cancer , 2006, Clinical Cancer Research.

[27]  D. Engelman,et al.  Invariant chain transmembrane domain trimerization: a step in MHC class II assembly. , 2006, Biochemistry.

[28]  D. Goldenberg,et al.  Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. , 2005, Blood.

[29]  P. Adegboyega,et al.  Polarized Expression of CD74 by Gastric Epithelial Cells , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[30]  S. Becker-Herman,et al.  CD74 is a member of the regulated intramembrane proteolysis-processed protein family. , 2005, Molecular biology of the cell.

[31]  M. Ogawa,et al.  Clinical significance of MHC class II-associated invariant chain expression in human gastric carcinoma. , 2005, Oncology reports.

[32]  G. Griffiths,et al.  Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys , 2005, Clinical Cancer Research.

[33]  K. Iczkowski,et al.  Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer , 2005, BMC Cancer.

[34]  D. Goldenberg,et al.  Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. , 2004, Blood.

[35]  David M. Goldenberg,et al.  CD74 Is Expressed by Multiple Myeloma and Is a Promising Target for Therapy , 2004, Clinical Cancer Research.

[36]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  E. von Hofe,et al.  Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules. , 2004, Current opinion in molecular therapeutics.

[38]  G. Griffiths,et al.  Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  L. Leng,et al.  MIF Signal Transduction Initiated by Binding to CD74 , 2003, The Journal of experimental medicine.

[40]  E. Weber,et al.  Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Benaroch,et al.  Asparagine endopeptidase can initiate the removal of the MHC class II invariant chain chaperone. , 2003, Immunity.

[42]  I. Shachar,et al.  Invariant chain-induced B cell differentiation requires intramembrane proteolytic release of the cytosolic domain. , 2002, Immunity.

[43]  R. Hershkoviz,et al.  Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Goldenberg,et al.  Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  M. Brechbiel,et al.  Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  G. Freeman,et al.  Expression of MHC Class II-Associated Invariant Chain (Ii;CD74) in Thymic Epithelial Neoplasms , 2000, Applied immunohistochemistry & molecular morphology : AIMM.

[47]  Minzhen Xu,et al.  Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells , 1999, Cancer Immunology, Immunotherapy.

[48]  S. Fulda,et al.  Cytotoxic drugs and the CD95 pathway , 1999, Leukemia.

[49]  Goldenberg,et al.  Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines , 1999, Immunology.

[50]  Santa Jeremy Ono,et al.  Cis-element dependence and occupancy of the human invariant chain promoter in CIITA-dependent and -independent transcription. , 1999, Molecular immunology.

[51]  P. Galle,et al.  The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis. , 1999, European cytokine network.

[52]  B. Mach,et al.  Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA , 1997, The EMBO journal.

[53]  G. Griffiths,et al.  Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. , 1996, The Biochemical journal.

[54]  R. Flavell,et al.  Requirement for Invariant Chain in B Cell Maturation and Function , 1996, Science.

[55]  H. Ploegh,et al.  Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. , 1996, Immunity.

[56]  P. Cresswell.  Invariant Chain Structure and MHC Class II Function , 1996, Cell.

[57]  K. Wright,et al.  Major Histocompatibility Complex Class II-associated Invariant Chain Gene Expression Is Up-regulated by Cooperative Interactions of Sp1 and NF-Y (*) , 1995, The Journal of Biological Chemistry.

[58]  K. Swier,et al.  Efficient internalization of MHC class II-invariant chain complexes is not sufficient for invariant chain proteolysis and class II antigen presentation. , 1995, Journal of immunology.

[59]  M. Zacheis,et al.  Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells. , 1995, Journal of immunology.

[60]  P. Cresswell,et al.  Structural analysis of proteolytic products of MHC class II-invariant chain complexes generated in vivo. , 1993, Journal of immunology.

[61]  G. Loss,et al.  Invariant chain retains MHC class II molecules in the endocytic pathway. , 1993, Journal of immunology.

[62]  L. Glimcher,et al.  B lymphocyte development and activation independent of MHC class II expression. , 1993, Journal of immunology.

[63]  G. Griffiths,et al.  A block in degradation of MHC class II-associated invariant chain correlates with a reduction in transport from endosome carrier vesicles to the prelysosome compartment. , 1992, Journal of cell science.

[64]  P. Cresswell,et al.  Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes. , 1992, Journal of immunology.

[65]  J. Neefjes,et al.  Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistance alpha beta heterodimers in endosomes. , 1992, The EMBO journal.

[66]  D. Gray,et al.  Mice lacking MHC class II molecules , 1991, Cell.

[67]  P. A. Peterson,et al.  Intracellular transport of class II MHC molecules directed by invariant chain , 1990, Nature.

[68]  L. Zhu,et al.  Transcriptional control of the invariant chain gene involves promoter and enhancer elements common to and distinct from major histocompatibility complex class II genes , 1990, Molecular and cellular biology.

[69]  D. Goldenberg,et al.  Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. , 1989, Cancer research.

[70]  P. Dellabona,et al.  Transcriptional control of MHC class II gene expression during differentiation from B cells to plasma cells. , 1989, Journal of immunology.

[71]  Eric O Long,et al.  Isolation of cDNA clones for the p33 invariant chain associated with HLA-DR antigens. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[72]  J. Strominger,et al.  Demonstration of structural polymorphism among HLA-DR light chains by two-dimensional gel electrophoresis , 1980, The Journal of experimental medicine.

[73]  C. Y. Wang,et al.  Patterns of expression of human "Ia-like" antigens during the terminal stages of B cell development. , 1978, Journal of immunology.

[74]  H. W. Casey,et al.  Basaloid adenomas of the mammary gland in beagle dogs administered investigational contraceptive steroids. , 1977, Journal of the National Cancer Institute.

[75]  M. Genuardi,et al.  Localization of the HLA class 11-associated invariant chain gene to human chromosome band 5832 , 2004, Immunogenetics.

[76]  R. Foà,et al.  Resistance to CD95-mediated apoptosis of CD40-activated chronic lymphocytic leukemia B cells is not related to lack of DISC molecules expression. , 2004, The hematology journal : the official journal of the European Haematology Association.

[77]  S. Pambuccian,et al.  Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications. , 1996, The American journal of surgical pathology.

[78]  H. Mcdevitt,et al.  Detection of a common polypeptide chain in I--A and I--E sub-region immunoprecipitates. , 1979, Molecular immunology.

[79]  M. Genuardi,et al.  Localization of the HLA class II-associated inva ¢ iant chain gene to human chromosome band 5 q 32 , 2022 .